🟢 MRNA is trading 4.8% up today, rebounding on continued FDA flu vaccine panel optimism

MRNA is trading 4.8% up at $62.17 as it rebounds from yesterday's sharp sell-off on continued optimism surrounding its flu vaccine pipeline.

• The stock is recovering after a 7.2% drop, driven by sustained momentum from recent positive FDA advisory panel support for the mRNA-1010 flu vaccine.
• The vaccine candidate remains a primary upside catalyst for investor sentiment regarding the strength of Moderna’s broader clinical pipeline.